Cancer – AGCT1532: Phase 3 Accelerated BEP Trial: A Ramdomized Phase 3 Trial of Accelerated vs. Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors
Condition or Therapy:
Intermediate and poor-risk metastatic germ cell tumors
Germ cell tumors, cisplatin, carboplatin, accelerated therapy
Study Number: ACGT1532
What is the goal of this study?
The overall goal of this study is to determine whether accelerated BEP will be effective and well-tolerated for patients with advanced germ cell tumors. We don't yet know if accelerated treatment is helpful in advanced germ cell tumors and we are hoping this study will answer that question.
Who can join the study?
This study may be a good fit for indidivuals with an intermediate and poorrisk metastatic germ cell tumor. For details about study eligibility, read more about this study on clinicaltrials.gov.
What will happen if my child takes part in this study?
In this study, partcipants will get 1 of 2 treatment plans: an accelerated plan and a standard plan. The drugs used in the 2 treatment plans are the same.
- The accelerated plan will be given every 2 weeks (14 days) for 4 cycles.
- The standard plan will be given every 3 weeks (21 days) for 4 cycles.
The word "cycle" is a term used to describe a period of time over which drugs are given. All participants, regardless of treatment group assigned, will receive 12 total doses of bleomycin. Patients in Arm A (standard) will receive 3 doses per cycle over 4 cycles. Patients in Arm B (accelerated) will receive 8 doeses of bleomycin (2 doses per cycle) over the first 4 cycles, then 4 doses of bleomycin (1 dose per week) over the remaining 4 weeks.
Who can I contact for more information?
To learn more, call 206-884-1214 or email the study coordinator.